Arecor Therapeutics plc (AREC.L) LSE
66.00
+0(+0.00%)
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
Arecor Therapeutics plc
Address
Chesterford Research Park
Little Chesterford, CB10 1XL
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 1223 426 060
Website
Sector
Healthcare
Industry
Biotechnology
Employees
50
First IPO Date
June 03, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Sarah Jennifer Howell | Chief Executive Officer & Executive Director | 520,000 | 1975 |
| David J. Ellam | Chief Financial Officer & Executive Director | 321,389 | 1964 |
| Jan Jezek | Chief Scientific Officer | 0 | N/A |
| David Gerring | Chief Development Officer | 0 | N/A |
Description
Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
